tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Aclaris Therapeutics Highlights Clinical Pipeline and Outlook
PremiumCompany AnnouncementsAclaris Therapeutics Highlights Clinical Pipeline and Outlook
30d ago
Aclaris Therapeutics: Promising Pipeline and Strategic Trials Justify Buy Rating
Premium
Ratings
Aclaris Therapeutics: Promising Pipeline and Strategic Trials Justify Buy Rating
1M ago
Aclaris Therapeutics initiates Phase 1a/1b program for ATI-052
Premium
The Fly
Aclaris Therapeutics initiates Phase 1a/1b program for ATI-052
1M ago
Wedbush bullish on Aclaris Therapeutics, initiates with an Outperform
PremiumThe FlyWedbush bullish on Aclaris Therapeutics, initiates with an Outperform
2M ago
Aclaris Therapeutics initiated with an Outperform at Wedbush
Premium
The Fly
Aclaris Therapeutics initiated with an Outperform at Wedbush
2M ago
Aclaris Therapeutics price target lowered to $16 from $20 at H.C. Wainwright
Premium
The Fly
Aclaris Therapeutics price target lowered to $16 from $20 at H.C. Wainwright
3M ago
Aclaris Therapeutics reports Q1 EPS (12c), consensus (12c)
PremiumThe FlyAclaris Therapeutics reports Q1 EPS (12c), consensus (12c)
3M ago
Aclaris Therapeutics appoints Hall as Chief Medical Officer
Premium
The Fly
Aclaris Therapeutics appoints Hall as Chief Medical Officer
3M ago
Aclaris Therapeutics: Promising Pipeline and Strategic Developments Justify Buy Rating
Premium
Ratings
Aclaris Therapeutics: Promising Pipeline and Strategic Developments Justify Buy Rating
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100